Uncovering the Biology of Type III Interferons
Event Details
- Type
- Other Seminars
- Speaker(s)
-
Evangelos Andreakos, Ph.D., professor and director, Biomedical Research Foundation Academy of Athens
- Speaker bio(s)
-
Evangelos Andreakos is Researcher (Professor Level) and Director of the Center of Clinical Research, Experimental Surgery and Translational Research of the Biomedical Research Foundation of the Academy of Athens (BRFAA). He studied Biochemistry at Imperial College London and did his PhD at the Kennedy Institute of Rheumatology in the UK under the supervision of Prof. Sir Marc Feldmann (2003 Lasker Award recipient). He then did his postdoc at the Kennedy Institute of Rheumatology on Toll-like receptors, immune cell signaling and inflammation under the supervision of Prof. Brian M. Foxwell. He subsequently moved as a research fellow to BRFAA, and was appointed as an Independent Investigator/Assistant Professor Level in Immunology in 2006. In 2013, he was promoted to Research Associate Professor and in 2018 to Research Director (Professor. Since 2022, he is Director of the Center of Clinical Research, Experimental Surgery and Translational Research of BRFAA. His research work seeks to understand how innate immunity, the body's natural defense against exogenous and endogenous insults, controls host protective versus host damaging inflammation. It particularly focuses on respiratory viral infections, trying to dissect the fine balance between effective host immunity and immunopathology, and how this can lead to the development of pneumonia and acute respiratory distress syndrome. A particular area of focus involves the unwinding of the biology of lambda Interferons in health and disease. His lab also investigates the role of innate immunity in chronic inflammation, and the development of chronic diseases such as asthma, obesity and atherosclerosis. He has published >135 articles in leading international journals including Nat Immunol, Immunity, Sci Immunol, Circulation, PNAS, Nat Genetics, Blood and others and has received >12.000 citations. He has given talks and seminars as an invited speaker in many international conferences, leading Universities and the pharmaceutical industry. He is a regular referee for high impact journals and an Expert Evaluator/Panel member for several funding bodies including the European Commission, the Agence Nationale de Recherche (France) and others. He has also been the Coordinator of EC-funded Consortia such as TO_AITION, RISKYCAD and TACIT, and Partner in several others (ATHEROREMO, ATHEROFLUX, CURE, TAXINOMISIS, IMMUNAID, LIVERTARGET, UNDINE).
- Open to
- Tri-Institutional